$NVO

Denmark's central bank raised its house price forecasts, predicting 8.6% growth in 2026, 4.6% in 2027, and 2.9% in 2028, outpacing neighboring countries. Novo's shares fell over 10% after presenting an updated strategy, including diversifying into liver and cardiovascular diseases, and launching five multi-blockbuster drugs by 2030. Electric car sales in Europe rose 62.7% year-over-year in August, with Denmark leading at 85.9% of new car sales being electric.

Novo Nordisk has cut 13,000 jobs over the past year to redirect resources toward R&D and new growth opportunities. The company faces competition in the obesity-drug market and upcoming patent expirations. Novo aims to launch over five blockbuster drugs by 2030 and expand into new treatment areas, according to the company.

The TSX closed Friday at 35,806.65, up 0.48% for the week. December futures rose 0.7% Monday. Traders await Bank of Canada Governor Tiff Macklem's speech for policy clues. Novo shares fell 7% after outlining growth plans in the obesity drug market. U.S. stock futures rallied as oil prices slid, with tensions in the Middle East and a U.S.-China summit in focus.

Novo Nordisk (NVO) is seeking a U.S. court injunction to block Eli Lilly's (LLY) ads for Zepbound and Mounjaro, alleging misleading claims. Lilly denies wrongdoing. Analysts expect LLY to lead the GLP-1 market, with Mounjaro and Zepbound driving sales. NVO is down 8% YTD, while LLY is up 9.8%.

Novo Nordisk (NVO) shares fell 3% on Wednesday, extending a 12% weekly decline, the worst since February. CEO Mike Doustdar mentioned a potential direct NYSE listing, but no active process exists. Singapore approved Wegovy for a new liver condition. Investors remain concerned about pricing, competition, and near-term performance, despite long-term growth targets and positive CagriSema trial results.

Florida sued Eli Lilly, Novo Nordisk, and pharmacy benefit managers, alleging they used rebates to maintain high drug prices, harming patients and independent pharmacies. The state claims these practices discouraged competition and limited access to affordable treatments, seeking damages and changes to pricing practices. The case focuses on insulin and GLP-1 medications, with Florida citing significant market power among the defendants.

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen expressed openness to a direct NYSE listing to attract U.S. investors. The U.S. contributes over half of Novo's revenue. The company faces competition from Eli Lilly (LLY) and recent pipeline setbacks, prompting strategic shifts and investor discussions on M&A.

Novo Nordisk's semaglutide (Ozempic, Wegovy) failed to slow Alzheimer's progression in trials EVOKE and EVOKE+. The drug showed no meaningful difference in memory decline compared to placebo, despite affecting some biological markers. The company announced the results in late 2025, with full findings published in 2026. The drug remains effective for diabetes and weight management, but not for Alzheimer's prevention or treatment.

Dozens of U.S. lawsuits target Novo Nordisk, Eli Lilly, and other manufacturers of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, alleging the medicines caused a rare eye condition (NAION) that can lead to permanent vision loss. Novo Nordisk denies the claims, while Eli Lilly is reviewing data. Research on the link remains inconclusive, and no NAION warning has been added to the drugs.

Novo NVO received positive CHMP recommendations for denecimig (Frehemgo) for hemophilia A and Sogroya (somapacitan) for idiopathic short stature in Europe. Denecimig offers flexible dosing and could launch in Europe in late 2026. Sogroya, if approved, would be the first growth hormone treatment for ISS in the EU. Novo's rare disease sales reached DKK 9.1 billion in H1 2026, with Sogroya contributing significantly.